Shares of vTv Therapeutics Inc (NASDAQ:VTVT) have received an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $16.00.
Separately, Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th.
In other news, major shareholder Ronald O. Perelman acquired 1,879,699 shares of the company’s stock in a transaction on Thursday, September 27th. The shares were bought at an average cost of $1.33 per share, with a total value of $2,499,999.67. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Ronald O. Perelman acquired 570,777 shares of the company’s stock in a transaction on Friday, August 10th. The stock was purchased at an average cost of $4.38 per share, for a total transaction of $2,500,003.26. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,335,175 shares of company stock worth $7,505,003. Insiders own 2.00% of the company’s stock.
An institutional investor recently raised its position in vTv Therapeutics stock. JPMorgan Chase & Co. raised its position in vTv Therapeutics Inc (NASDAQ:VTVT) by 55.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 327,728 shares of the biotechnology company’s stock after purchasing an additional 117,513 shares during the period. JPMorgan Chase & Co. owned 1.00% of vTv Therapeutics worth $1,333,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 2.34% of the company’s stock.
Shares of VTVT opened at $2.58 on Monday. vTv Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $8.40.
vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Friday, August 3rd. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The company had revenue of $2.47 million for the quarter, compared to analysts’ expectations of $2.46 million. On average, equities analysts forecast that vTv Therapeutics will post -0.92 earnings per share for the current year.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Featured Article: What Does Beta Mean In Stock Selection
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.